Board professional Eva Sjökvist Saers new chairman of Dicot

Press release: Uppsala, February 9, 2021. At an Extraordinary General Meeting on February 9, Dr Eva Sjökvist Saers was elected new Chairman of the Board of Dicot, which is developing a potency drug for erectile dysfunction and premature ejaculation. Eva acts as a board member in several life science companies, she is chairman of Vinnova's strategic innovation program Swelife and has an industrial background from AstraZeneca and as CEO of APL.

On February 9, a unanimous meeting elected Dr Eva Sjökvist Saers as the new Chairman of the Board of the pharmaceutical company Dicot. She thereby replaces Lars Jonsson, who remains as a member of the board.

Dr Sjökvist Saers's 25-year career in life science began immediately after her dissertation in pharmaceutical science when she was recruited to a management role at Astra. There she was, among other things, head of the pharmaceutical research unit at Astra Pain Control. After the merger of Astra and Zeneca, Eva worked with R&D-related strategies for the new company.

As CEO of APL, she took the company from being part of the state pharmacy monopoly to a competitive independent company. In a couple of years, sales almost tripled and went from SEK 500 million to SEK 1.3 billion. During the years 2008-2016, Eva was the first ever female chairman of the board of The Pharmacy Society, which dates to the 17th century and today is a modern organization for professionals.

Eva currently works as a professional board member in several life science companies such as Recipharm and Bluefish Pharmaceuticals. She is also chairman of Vinnova's strategic innovation program Swelife.

"The research and development conducted in Dicot has an exciting ethnopharmacological background. It appeals to me as a pharmacist with long experience of drug development. What Dicot is working on is really not a lifestyle medicine. This is about a serious disruption of a basic human instinct. If you can produce a modern, well-functioning drug it makes a big difference. Drug development is however complex and achieving commercial success requires hard and purposeful work of different skills. I will contribute with my experience from leading and running businesses and with my network in life science", says Eva Sjökvist Saers.

"Eva brings industrial competence and experience in both the research field and the commercial part of entrepreneurship. Her proven capacity to modernize and develop businesses will be a major contribution during the progressive phase Dicot is in", Dicot's CEO Göran Beijer comments.

For further information, please contact:

Göran Beijer, CEO

Tel: +46 70-663 60 09

Email: [email protected]

About Dicot AB

Dicot is developing the drug candidate LIB-01 (formerly Libiguin), which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion.

Research and development is conducted under own auspices up to phase 1 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 1,800 shareholders. For more information, please visit:

Om Dicot Pharma

Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.



Kurs ()
Förändring ()
Marknad Spotlight Stock Market Kortnamn DICOT ISIN-kod SE0011178458


Elin Trampe Vd